RLYBHealthcare · BiotechnologyRLYB Stock Forecast: Rallybio Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 12 Sept 2026 — in the upper half.
RLYB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Rallybio Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Value (16): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
RLYB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RLYB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Apr 2025 | Jones Trading | Downgrade | Hold | — |
| 9 Apr 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Aug 2024 | Evercore ISI Group | Maintains | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2024 | JP Morgan | Downgrade | Neutral | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 18 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 11 Apr 2024 | Wedbush | Maintains | Outperform | — |
| 13 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2024 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLYB appears on the weeks it earns a place.
RLYB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Rallybio Corp. returned +256.3% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RLYB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Rallybio Corp. (RLYB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.1×
- Price / sales
- 138.7×
- Price / book
- 0.9×
- EV / EBITDA
- 0.1×
Cheaper than 69% of US stocks
Cheaper than 3% of US stocks
Cheaper than 75% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −3935.4%
- Net margin
- 7051.2%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 99% of US stocks
- Return on equity
- 64.9%
- Return on assets
- −21.3%
- Dividend yield
- —
Higher than 94% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Rallybio Corp. (RLYB) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rallybio Corp. has a market value of $89.6M and an enterprise value of −$3.2M.
Revenue in the twelve months to 30 June 2026: $646K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: $45.6M, a 7051.2% net margin.
Free cash flow in the twelve months to 30 June 2026: $26.7M.
Trailing P/E: 2.1×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Rallybio Corp. employs 7 people — $92K of revenue per employee.
Data provided by Twelve Data
RLYB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rallybio Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about RLYB stock
Is RLYB stock a buy right now?
Of the 1 analysts covering Rallybio Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rallybio Corp. 59 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RLYB?
As at 12 Sept 2026, Rallybio Corp. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
What is the RLYB stock forecast for 2030?
No analyst covering Rallybio Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLYB are extrapolating price history, which says nothing about the business.
How has RLYB stock performed over the past year?
Rallybio Corp. returned +256.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rallybio Corp. do?
Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases.
About Rallybio Corp.
Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. The company’s current pipeline centers on areas such as complement dysregulation, hematology, maternal-fetal health, and iron overload disorders. Its lead programs include RLYB116, a complement component 5 inhibitor being developed for diseases driven by complement dysregulation, and RLYB332, a preclinical antibody candidate for iron overload-related conditions. Rallybio also works on therapies for rare maternal-fetal disorders, reflecting its emphasis on areas with significant unmet medical need. Headquartered in New Haven, Connecticut, Rallybio operates as a focused drug development company in the biotechnology sector, advancing specialized treatments designed for patients with serious, underserved conditions.
CEO Dr. Stephen Uden M.D., MBBS · 7 employees · United States · https://www.rallybio.com